4 results on '"Diane Calinski"'
Search Results
2. Structural flexibility of the G alpha s alpha-helical domain in the beta2-adrenoceptor Gs complex
- Author
-
Gerwin H, Westfield, Søren G F, Rasmussen, Min, Su, Somnath, Dutta, Brian T, DeVree, Ka Young, Chung, Diane, Calinski, Gisselle, Velez-Ruiz, Austin N, Oleskie, Els, Pardon, Pil Seok, Chae, Tong, Liu, Sheng, Li, Virgil L, Woods, Jan, Steyaert, Brian K, Kobilka, Roger K, Sunahara, and Georgios, Skiniotis
- Subjects
Models, Molecular ,Protein Conformation ,Biological Sciences ,Crystallography, X-Ray ,Guanosine Diphosphate ,Protein Structure, Secondary ,Protein Structure, Tertiary ,Microscopy, Electron ,Guanosine 5'-O-(3-Thiotriphosphate) ,GTP-Binding Protein alpha Subunits, Gs ,Animals ,Guanosine Triphosphate ,Receptors, Adrenergic, beta-2 ,Crystallization ,Protein Binding - Abstract
The active-state complex between an agonist-bound receptor and a guanine nucleotide-free G protein represents the fundamental signaling assembly for the majority of hormone and neurotransmitter signaling. We applied single-particle electron microscopy (EM) analysis to examine the architecture of agonist-occupied β(2)-adrenoceptor (β(2)AR) in complex with the heterotrimeric G protein Gs (Gαsβγ). EM 2D averages and 3D reconstructions of the detergent-solubilized complex reveal an overall architecture that is in very good agreement with the crystal structure of the active-state ternary complex. Strikingly however, the α-helical domain of Gαs appears highly flexible in the absence of nucleotide. In contrast, the presence of the pyrophosphate mimic foscarnet (phosphonoformate), and also the presence of GDP, favor the stabilization of the α-helical domain on the Ras-like domain of Gαs. Molecular modeling of the α-helical domain in the 3D EM maps suggests that in its stabilized form it assumes a conformation reminiscent to the one observed in the crystal structure of Gαs-GTPγS. These data argue that the α-helical domain undergoes a nucleotide-dependent transition from a flexible to a conformationally stabilized state.
- Published
- 2011
3. Structural flexibility of the Gαs α-helical domain in the β2-adrenoceptor Gs complex
- Author
-
Min Su, Brian T. DeVree, Sheng Li, Gisselle A. Vélez-Ruiz, Diane Calinski, Austin N. Oleskie, Brian Kobilka, Tong Liu, Gerwin Westfield, Pil Seok Chae, Ka Young Chung, Jan Steyaert, Søren G. F. Rasmussen, Georgios Skiniotis, Roger K. Sunahara, Somnath Dutta, Els Pardon, Virgil L. Woods, Structural Biology Brussels, and Department of Bio-engineering Sciences
- Subjects
Crystallography ,Multidisciplinary ,Gs alpha subunit ,Protein structure ,GPCR ,Molecular model ,G protein ,Chemistry ,Heterotrimeric G protein ,GTP-Binding Protein alpha Subunits ,Biophysics ,Ternary complex ,G protein-coupled receptor - Abstract
The active-state complex between an agonist-bound receptor and a guanine nucleotide-free G protein represents the fundamental signaling assembly for the majority of hormone and neurotransmitter signaling. We applied single-particle electron microscopy (EM) analysis to examine the architecture of agonist-occupied β 2 -adrenoceptor (β 2 AR) in complex with the heterotrimeric G protein Gs (Gαsβγ). EM 2D averages and 3D reconstructions of the detergent-solubilized complex reveal an overall architecture that is in very good agreement with the crystal structure of the active-state ternary complex. Strikingly however, the α-helical domain of Gαs appears highly flexible in the absence of nucleotide. In contrast, the presence of the pyrophosphate mimic foscarnet (phosphonoformate), and also the presence of GDP, favor the stabilization of the α-helical domain on the Ras-like domain of Gαs. Molecular modeling of the α-helical domain in the 3D EM maps suggests that in its stabilized form it assumes a conformation reminiscent to the one observed in the crystal structure of Gαs-GTPγS. These data argue that the α-helical domain undergoes a nucleotide-dependent transition from a flexible to a conformationally stabilized state.
- Published
- 2011
4. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.
- Author
-
Xiang Ling, Diane Calinski, Asher A Chanan-Khan, Muxiang Zhou, and Fengzhi Li
- Subjects
- *
CANCER patients , *GENE expression , *CELL receptors , *CANCER cells , *APOPTOSIS , *DRUG resistance , *FLOW cytometry , *CELL lines , *CANCER treatment - Abstract
Background: Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear. There are conflicting reports for the effect of bortezomib on survivin expression, which lacks of a plausible explanation. Methods: In this study, we tested cancer cells with both p53 wild type and mutant/null background for the relationship of bortezomib resistance with survivin expression and p53 status using MTT assay, flow cytometry, DNA fragmentation, caspase activation, western blots and RNAi technology. Results: We found that cancer cells with wild type p53 show a low level expression of survivin and are sensitive to treatment with bortezomib, while cancer cells with a mutant or null p53 show a high level expression of survivin and are resistant to bortezomib-mediated apoptosis induction. However, silencing of survivin expression utilizing survivin mRNA-specific siRNA/shRNA in p53 mutant or null cells sensitized cancer cells to bortezomib mediated apoptosis induction, suggesting a role for survivin in bortezomib resistance. We further noted that modulation of survivin expression by bortezomib is dependent on p53 status but independent of cancer cell types. In cancer cells with mutated p53 or p53 null, bortezomib appears to induce survivin expression, while in cancer cells with wild type p53, bortezomib downregulates or shows no significant effect on survivin expression, which is dependent on the drug concentration, cell line and exposure time. Conclusions: Our findings, for the first time, unify the current inconsistent findings for bortezomib treatment and survivin expression, and linked the effect of bortezomib on survivin expression, apoptosis induction and bortezomib resistance in the relationship with p53 status, which is independent of cancer cell types. Further mechanistic studies along with this line may impact the optimal clinical application of bortezomib in solid cancer therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.